---
title: "Orforglipron: Dosing & Vendor Prices — BodyHackGuide"
description: "Orforglipron: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices."
lang: en
json-ld: |
  [
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.bodyhackguide.co/"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Compounds",
          "item": "https://www.bodyhackguide.co/compare"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Orforglipron"
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Product",
      "name": "Orforglipron",
      "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
      "url": "https://www.bodyhackguide.co/compound/orforglipron",
      "image": "https://www.bodyhackguide.co/og-image.png",
      "brand": {
        "@type": "Brand",
        "name": "Research Compound"
      },
      "offers": {
        "@type": "AggregateOffer",
        "lowPrice": "249.99",
        "highPrice": "249.99",
        "priceCurrency": "USD",
        "offerCount": "1",
        "availability": "https://schema.org/InStock",
        "offers": [
          {
            "@type": "Offer",
            "price": "249.99",
            "priceCurrency": "USD",
            "availability": "https://schema.org/InStock",
            "itemCondition": "https://schema.org/NewCondition",
            "url": "https://www.vandl-labs.com/product/orforglipron/?ref=choncho",
            "seller": {
              "@type": "Organization",
              "name": "VANDL Labs",
              "url": "https://www.vandl-labs.com/?ref=choncho"
            }
          }
        ]
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "Orforglipron",
      "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
      "lastReviewed": "2026-08-27T00:34:39.694Z",
      "url": "https://www.bodyhackguide.co/compound/orforglipron",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "Orforglipron",
        "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
        "activeIngredient": "Orforglipron",
        "mechanismOfAction": "Orforglipron (LY3502970; OWL833) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist. It engages the GLP-1 receptor (GLP1R) through a binding mode fundamentally different from native GLP-1 or peptide-based analogs. Non-Peptide Binding at a Distinct Receptor Pocket: Native GLP-1 is a 30-amino-acid peptide whose helix docks into the GLP1R orthosteric site to drive activation - the same general region used by semaglutide, liraglutide, and other peptide analogs. Orforglipron, a small molecule, instead occupies a distinct pocket in the upper helical bundle of the receptor, contacting the extracellular domain (ECD), extracellular loop 2 (ECL2), and transmembrane helices 1, 2, 3, and 7. A high-resolution cryo-EM structure of orforglipron bound to active-state GLP1R showed this creates a unique receptor conformation not adopted with peptide ligands ([Kawai et al., 2020]). Partial, G-Protein-Biased Agonism (not a full agonist): Contrary to the assumption that it simply reproduces peptide-agonist pharmacology, orforglipron is a PARTIAL agonist that is BIASED toward Gs/cAMP signaling over beta-arrestin recruitment at GLP1R ([Kawai et al., 2020]). Because the Gs/cAMP/PKA arm is the pathway that drives the therapeutically important physiology, this partial, biased profile still delivers robust clinical efficacy, including: Beta-cell insulin secretion (glucose-dependent) Alpha-cell glucagon suppression Hypothalamic POMC/CART neuron activation (appetite suppression) Brainstem vagal satiety signaling Gastric emptying delay Pharmacokinetic Profile: Orforglipron's PK enables once-daily oral dosing: Oral bioavailability: HIGH - mean absolute oral bioavailability ~79% in a human mass-balance study, in sharp contrast to oral semaglutide (Rybelsus, ~1%, which needs the SNAC absorption enhancer) ([Morse et al., 2025]) Half-life: ~29-49 hours - long enough for once-daily steady-state dosing ([Pratt et al., 2023]) Tmax: ~6-10 hours after oral administration Not a substrate for the peptidase DPP-4 (it is not a peptide) and not subject to gastric-acid degradation No clinically meaningful food effect: unlike Rybelsus it can be taken with or without food and with no post-dose fasting window, removing the biggest compliance problem of oral semaglutide Metabolic Effects (downstream of receptor activation): Once orforglipron activates GLP1R, the downstream physiology parallels other GLP-1 agonists: Weight loss: primarily via appetite suppression and reduced food intake Glycemic control: meaningful HbA1c reduction in type 2 diabetes via glucose-dependent insulin secretion and glucagon suppression Gastric emptying: delayed, contributing to satiety Cardiometabolic: pooled Phase 2 data showed placebo-adjusted improvements in blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP ([Wharton et al., 2025]) Why \"Non-Peptide\" Matters: The small-molecule structure can be made by conventional chemical synthesis (not peptide synthesis or fermentation), is orally and chemically stable, needs no refrigeration, and largely avoids the immunogenicity (anti-drug antibody) risk that can affect peptide drugs. Relation to the Injectable GLP-1 Class: Orforglipron is not structurally related to exendin-4, GLP-1, or semaglutide. It originated from Chugai's OWL833 small-molecule program (developed with Eli Lilly as LY3502970), identified by screening and medicinal-chemistry optimization to yield a novel chemotype that activates the same receptor - analogous to how small-molecule opioid agonists activate the same receptors as endogenous peptide opioids without sharing their peptide structure.",
        "dosageForm": "capsule",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "What makes orforglipron different from oral semaglutide (Rybelsus)?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist with high oral bioavailability (~79% absolute in human mass-balance studies), so it can be taken any time of day with or without food. Rybelsus is oral semaglutide - still a peptide - that relies on the absorption enhancer SNAC, has only ~1% oral bioavailability, and must be taken fasting with a small amount of water and a 30-minute wait before eating or drinking. Those practical differences translate into large efficacy gaps: at its top dose orforglipron produced ~12.4% weight loss at 72 weeks in Phase 3 (ATTAIN-1), versus roughly 3-5% typically seen with Rybelsus (Morse et al., 2025)."
          }
        },
        {
          "@type": "Question",
          "name": "How does orforglipron's weight loss compare to injectable semaglutide or tirzepatide?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "In the Phase 3 ATTAIN-1 trial, orforglipron 36 mg once daily produced ~12.4% mean weight loss (about 27.3 lb) at 72 weeks. That is meaningful for an oral drug, but it came in somewhat below injectable semaglutide 2.4 mg weekly (Wegovy, ~15% at 68 weeks in STEP-1) and well below tirzepatide 15 mg weekly (Zepbound, ~20-21% at 72 weeks in SURMOUNT-1, which adds GIP agonism). So orforglipron does not fully match the strongest injectables - its real advantage is being an oral pill with no food or water timing restrictions, which for a patient who refuses injections is a major benefit."
          }
        },
        {
          "@type": "Question",
          "name": "When will orforglipron be available by prescription?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "It is already available in the US. The FDA approved orforglipron on April 1, 2026 under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. Eli Lilly has also filed for weight management and/or type 2 diabetes in dozens of other countries, with the type 2 diabetes indication still under regulatory review in the US. Because it is a small molecule made by conventional chemical synthesis, supply is expected to scale far faster than injectable peptide GLP-1s did."
          }
        },
        {
          "@type": "Question",
          "name": "How is orforglipron's mechanism different from other GLP-1 agonists?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Peptide GLP-1 agonists (semaglutide, liraglutide, and the GLP-1 arm of tirzepatide) engage the receptor's orthosteric site the way native GLP-1 does. Orforglipron, a small molecule, instead binds a distinct pocket in the upper helical bundle of GLP1R - contacting the extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7 - producing a unique active-state receptor conformation. Pharmacologically it behaves as a partial agonist that is biased toward Gas/cAMP signaling over beta-arrestin recruitment; because the Gas/cAMP arm drives the insulinotropic and appetite-suppressing effects, it still delivers strong clinical efficacy (Kawai et al., 2020)."
          }
        },
        {
          "@type": "Question",
          "name": "Can orforglipron be combined with other weight loss medications?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Most evidence supports combining orforglipron with mechanism-distinct agents rather than other GLP-1 agonists (which would be redundant). Leading combinations: (1) amylin analog like Cagrilintide - Novo Nordisk's CagriSema concept shows ~22.7% weight loss with semaglutide + cagrilintide; orforglipron + cagrilintide should produce similar synergy; (2) SGLT2 inhibitors for T2D - complementary mechanisms with additive glycemic and weight benefits; (3) metformin - standard T2D foundation. Avoid combining orforglipron with other GLP-1 agonists, other GLP-1 receptor modulators, or Tirzepatide / Retatrutide / Mazdutide, which would be pharmacologically redundant at the GLP-1 receptor."
          }
        },
        {
          "@type": "Question",
          "name": "What side effects should I expect on orforglipron?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Expect gastrointestinal symptoms similar to all GLP-1 agonists: nausea (30-50% at therapeutic doses), diarrhea or constipation (20-30%), vomiting (10-20%), reduced appetite (expected therapeutic effect but can feel uncomfortable early). These usually peak during dose escalations and improve within 1-2 weeks at each step. Gradual dose titration significantly reduces intolerance versus faster escalation. Less common but serious: pancreatitis (rare, requires evaluation if severe abdominal pain develops), gallbladder disease (weight loss-related), retinopathy worsening (in patients with existing diabetic retinopathy during rapid glycemic improvement). Long-term theoretical concerns include medullary thyroid carcinoma (rodent signal, no clear human signal), warranting the MTC/MEN2 contraindication shared across the GLP-1 class (Fras et al., 2023)."
          }
        },
        {
          "@type": "Question",
          "name": "Will I regain weight if I stop taking orforglipron?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, most patients regain substantial weight within 12 months of discontinuation. This mirrors the pattern seen with semaglutide (STEP-4 extension trial: ~2/3 of weight regained by 1 year off-drug) and tirzepatide (SURMOUNT-4: similar pattern). GLP-1 agonists are best understood as chronic therapy for chronic disease - analogous to how antihypertensives control blood pressure only while taken. Patients considering orforglipron should plan for long-term or lifelong therapy, with structured lifestyle support (resistance training, protein-forward nutrition, sleep optimization) to maximize the weight maintained if discontinuation becomes necessary. Some patients successfully transition to maintenance doses (e.g., 12 mg daily instead of 36 mg) to sustain partial benefit at lower cost and side effects."
          }
        },
        {
          "@type": "Question",
          "name": "How does orforglipron affect body composition versus just total weight?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Like all GLP-1 agonists, orforglipron produces primarily fat-mass loss but also some lean-mass loss - typically 20-40% of total weight lost is lean tissue. This is a well-documented class effect seen with semaglutide (STEP-1 DEXA substudy), tirzepatide (SURMOUNT DEXA data), and expected for orforglipron. Mitigation strategies include: (1) resistance training 2-3x/week minimum - the single most impactful intervention for lean mass preservation; (2) high-protein intake of 1.2-1.6 g/kg body weight daily; (3) adequate overall calories to support muscle protein synthesis; (4) consideration of adjunctive growth-hormone-axis support such as Tesamorelin, Ipamorelin, or CJC-1295 for patients prioritizing lean mass preservation. DEXA scans every 6-12 months allow objective tracking of body composition changes rather than relying on scale weight alone."
          }
        },
        {
          "@type": "Question",
          "name": "Is orforglipron safe for people with type 1 diabetes?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Orforglipron is not indicated for type 1 diabetes. Its primary mechanisms - glucose-dependent insulin secretion and glucagon suppression - require functional pancreatic beta cells, which T1D patients lack. Using orforglipron in T1D risks diabetic ketoacidosis (DKA) if insulin doses are inappropriately reduced in response to modest glycemic improvement, and the drug adds complexity without clear benefit. Some T1D patients with obesity have explored off-label GLP-1 agonist use to support weight loss with variable results and increased complexity; this should only be done with close endocrinology supervision and intensive monitoring. FDA approval for orforglipron (Foundayo) is for chronic weight management in obesity/overweight, with a type 2 diabetes indication still under review; type 1 diabetes use would be off-label and experimental."
          }
        },
        {
          "@type": "Question",
          "name": "Why is orforglipron a big deal beyond just being oral?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The transformational implications extend beyond convenience: (1) Manufacturing scale: small-molecule synthesis uses existing generic drug manufacturing infrastructure, potentially easing the peptide supply crisis that caused 2+ year semaglutide shortages and limited tirzepatide rollout; (2) Global access: no cold-chain requirement means distribution to low- and middle-income countries becomes feasible - currently injectable GLP-1s are essentially unavailable across much of Africa, South America, and Southeast Asia due to refrigeration logistics; (3) Cost reduction: generic competition after patent expiration (mid-2030s) could bring retail cost from $1,000+/month to potentially $20-50/month, analogous to how statins democratized cholesterol management; (4) Patient barrier removal: ~30-40% of candidates for injectable GLP-1s decline due to needle aversion; orforglipron removes this barrier entirely; (5) Development platform: success validates small-molecule agonism of peptide receptors as a drug-discovery strategy, opening the door to oral versions of other peptide drug classes (e.g., GIP agonists, glucagon agonists, incretin combinations). The FDA's approval of orforglipron (Foundayo) in April 2026 marks the beginning of the oral GLP-1 era and likely the peak of the injectable-peptide era - a shift with major public health consequences."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    },
    {
      "@context": "https://schema.org",
      "@type": "Product",
      "name": "Orforglipron",
      "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
      "url": "https://www.bodyhackguide.co/compound/orforglipron",
      "image": "https://www.bodyhackguide.co/og-image.png",
      "brand": {
        "@type": "Brand",
        "name": "Research Compound"
      },
      "offers": {
        "@type": "AggregateOffer",
        "lowPrice": "249.99",
        "highPrice": "249.99",
        "priceCurrency": "USD",
        "offerCount": "1",
        "availability": "https://schema.org/InStock",
        "offers": [
          {
            "@type": "Offer",
            "price": "249.99",
            "priceCurrency": "USD",
            "availability": "https://schema.org/InStock",
            "itemCondition": "https://schema.org/NewCondition",
            "url": "https://www.vandl-labs.com/product/orforglipron/?ref=choncho",
            "seller": {
              "@type": "Organization",
              "name": "VANDL Labs",
              "url": "https://www.vandl-labs.com/?ref=choncho"
            }
          }
        ]
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "Orforglipron",
      "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
      "lastReviewed": "2026-08-27T00:34:39.694Z",
      "url": "https://www.bodyhackguide.co/compound/orforglipron",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "Orforglipron",
        "description": "Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).",
        "activeIngredient": "Orforglipron",
        "mechanismOfAction": "Orforglipron (LY3502970; OWL833) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist. It engages the GLP-1 receptor (GLP1R) through a binding mode fundamentally different from native GLP-1 or peptide-based analogs. Non-Peptide Binding at a Distinct Receptor Pocket: Native GLP-1 is a 30-amino-acid peptide whose helix docks into the GLP1R orthosteric site to drive activation - the same general region used by semaglutide, liraglutide, and other peptide analogs. Orforglipron, a small molecule, instead occupies a distinct pocket in the upper helical bundle of the receptor, contacting the extracellular domain (ECD), extracellular loop 2 (ECL2), and transmembrane helices 1, 2, 3, and 7. A high-resolution cryo-EM structure of orforglipron bound to active-state GLP1R showed this creates a unique receptor conformation not adopted with peptide ligands ([Kawai et al., 2020]). Partial, G-Protein-Biased Agonism (not a full agonist): Contrary to the assumption that it simply reproduces peptide-agonist pharmacology, orforglipron is a PARTIAL agonist that is BIASED toward Gs/cAMP signaling over beta-arrestin recruitment at GLP1R ([Kawai et al., 2020]). Because the Gs/cAMP/PKA arm is the pathway that drives the therapeutically important physiology, this partial, biased profile still delivers robust clinical efficacy, including: Beta-cell insulin secretion (glucose-dependent) Alpha-cell glucagon suppression Hypothalamic POMC/CART neuron activation (appetite suppression) Brainstem vagal satiety signaling Gastric emptying delay Pharmacokinetic Profile: Orforglipron's PK enables once-daily oral dosing: Oral bioavailability: HIGH - mean absolute oral bioavailability ~79% in a human mass-balance study, in sharp contrast to oral semaglutide (Rybelsus, ~1%, which needs the SNAC absorption enhancer) ([Morse et al., 2025]) Half-life: ~29-49 hours - long enough for once-daily steady-state dosing ([Pratt et al., 2023]) Tmax: ~6-10 hours after oral administration Not a substrate for the peptidase DPP-4 (it is not a peptide) and not subject to gastric-acid degradation No clinically meaningful food effect: unlike Rybelsus it can be taken with or without food and with no post-dose fasting window, removing the biggest compliance problem of oral semaglutide Metabolic Effects (downstream of receptor activation): Once orforglipron activates GLP1R, the downstream physiology parallels other GLP-1 agonists: Weight loss: primarily via appetite suppression and reduced food intake Glycemic control: meaningful HbA1c reduction in type 2 diabetes via glucose-dependent insulin secretion and glucagon suppression Gastric emptying: delayed, contributing to satiety Cardiometabolic: pooled Phase 2 data showed placebo-adjusted improvements in blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP ([Wharton et al., 2025]) Why \"Non-Peptide\" Matters: The small-molecule structure can be made by conventional chemical synthesis (not peptide synthesis or fermentation), is orally and chemically stable, needs no refrigeration, and largely avoids the immunogenicity (anti-drug antibody) risk that can affect peptide drugs. Relation to the Injectable GLP-1 Class: Orforglipron is not structurally related to exendin-4, GLP-1, or semaglutide. It originated from Chugai's OWL833 small-molecule program (developed with Eli Lilly as LY3502970), identified by screening and medicinal-chemistry optimization to yield a novel chemotype that activates the same receptor - analogous to how small-molecule opioid agonists activate the same receptors as endogenous peptide opioids without sharing their peptide structure.",
        "dosageForm": "capsule",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "What makes orforglipron different from oral semaglutide (Rybelsus)?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist with high oral bioavailability (~79% absolute in human mass-balance studies), so it can be taken any time of day with or without food. Rybelsus is oral semaglutide - still a peptide - that relies on the absorption enhancer SNAC, has only ~1% oral bioavailability, and must be taken fasting with a small amount of water and a 30-minute wait before eating or drinking. Those practical differences translate into large efficacy gaps: at its top dose orforglipron produced ~12.4% weight loss at 72 weeks in Phase 3 (ATTAIN-1), versus roughly 3-5% typically seen with Rybelsus (Morse et al., 2025)."
          }
        },
        {
          "@type": "Question",
          "name": "How does orforglipron's weight loss compare to injectable semaglutide or tirzepatide?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "In the Phase 3 ATTAIN-1 trial, orforglipron 36 mg once daily produced ~12.4% mean weight loss (about 27.3 lb) at 72 weeks. That is meaningful for an oral drug, but it came in somewhat below injectable semaglutide 2.4 mg weekly (Wegovy, ~15% at 68 weeks in STEP-1) and well below tirzepatide 15 mg weekly (Zepbound, ~20-21% at 72 weeks in SURMOUNT-1, which adds GIP agonism). So orforglipron does not fully match the strongest injectables - its real advantage is being an oral pill with no food or water timing restrictions, which for a patient who refuses injections is a major benefit."
          }
        },
        {
          "@type": "Question",
          "name": "When will orforglipron be available by prescription?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "It is already available in the US. The FDA approved orforglipron on April 1, 2026 under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. Eli Lilly has also filed for weight management and/or type 2 diabetes in dozens of other countries, with the type 2 diabetes indication still under regulatory review in the US. Because it is a small molecule made by conventional chemical synthesis, supply is expected to scale far faster than injectable peptide GLP-1s did."
          }
        },
        {
          "@type": "Question",
          "name": "How is orforglipron's mechanism different from other GLP-1 agonists?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Peptide GLP-1 agonists (semaglutide, liraglutide, and the GLP-1 arm of tirzepatide) engage the receptor's orthosteric site the way native GLP-1 does. Orforglipron, a small molecule, instead binds a distinct pocket in the upper helical bundle of GLP1R - contacting the extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7 - producing a unique active-state receptor conformation. Pharmacologically it behaves as a partial agonist that is biased toward Gas/cAMP signaling over beta-arrestin recruitment; because the Gas/cAMP arm drives the insulinotropic and appetite-suppressing effects, it still delivers strong clinical efficacy (Kawai et al., 2020)."
          }
        },
        {
          "@type": "Question",
          "name": "Can orforglipron be combined with other weight loss medications?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Most evidence supports combining orforglipron with mechanism-distinct agents rather than other GLP-1 agonists (which would be redundant). Leading combinations: (1) amylin analog like Cagrilintide - Novo Nordisk's CagriSema concept shows ~22.7% weight loss with semaglutide + cagrilintide; orforglipron + cagrilintide should produce similar synergy; (2) SGLT2 inhibitors for T2D - complementary mechanisms with additive glycemic and weight benefits; (3) metformin - standard T2D foundation. Avoid combining orforglipron with other GLP-1 agonists, other GLP-1 receptor modulators, or Tirzepatide / Retatrutide / Mazdutide, which would be pharmacologically redundant at the GLP-1 receptor."
          }
        },
        {
          "@type": "Question",
          "name": "What side effects should I expect on orforglipron?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Expect gastrointestinal symptoms similar to all GLP-1 agonists: nausea (30-50% at therapeutic doses), diarrhea or constipation (20-30%), vomiting (10-20%), reduced appetite (expected therapeutic effect but can feel uncomfortable early). These usually peak during dose escalations and improve within 1-2 weeks at each step. Gradual dose titration significantly reduces intolerance versus faster escalation. Less common but serious: pancreatitis (rare, requires evaluation if severe abdominal pain develops), gallbladder disease (weight loss-related), retinopathy worsening (in patients with existing diabetic retinopathy during rapid glycemic improvement). Long-term theoretical concerns include medullary thyroid carcinoma (rodent signal, no clear human signal), warranting the MTC/MEN2 contraindication shared across the GLP-1 class (Fras et al., 2023)."
          }
        },
        {
          "@type": "Question",
          "name": "Will I regain weight if I stop taking orforglipron?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, most patients regain substantial weight within 12 months of discontinuation. This mirrors the pattern seen with semaglutide (STEP-4 extension trial: ~2/3 of weight regained by 1 year off-drug) and tirzepatide (SURMOUNT-4: similar pattern). GLP-1 agonists are best understood as chronic therapy for chronic disease - analogous to how antihypertensives control blood pressure only while taken. Patients considering orforglipron should plan for long-term or lifelong therapy, with structured lifestyle support (resistance training, protein-forward nutrition, sleep optimization) to maximize the weight maintained if discontinuation becomes necessary. Some patients successfully transition to maintenance doses (e.g., 12 mg daily instead of 36 mg) to sustain partial benefit at lower cost and side effects."
          }
        },
        {
          "@type": "Question",
          "name": "How does orforglipron affect body composition versus just total weight?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Like all GLP-1 agonists, orforglipron produces primarily fat-mass loss but also some lean-mass loss - typically 20-40% of total weight lost is lean tissue. This is a well-documented class effect seen with semaglutide (STEP-1 DEXA substudy), tirzepatide (SURMOUNT DEXA data), and expected for orforglipron. Mitigation strategies include: (1) resistance training 2-3x/week minimum - the single most impactful intervention for lean mass preservation; (2) high-protein intake of 1.2-1.6 g/kg body weight daily; (3) adequate overall calories to support muscle protein synthesis; (4) consideration of adjunctive growth-hormone-axis support such as Tesamorelin, Ipamorelin, or CJC-1295 for patients prioritizing lean mass preservation. DEXA scans every 6-12 months allow objective tracking of body composition changes rather than relying on scale weight alone."
          }
        },
        {
          "@type": "Question",
          "name": "Is orforglipron safe for people with type 1 diabetes?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Orforglipron is not indicated for type 1 diabetes. Its primary mechanisms - glucose-dependent insulin secretion and glucagon suppression - require functional pancreatic beta cells, which T1D patients lack. Using orforglipron in T1D risks diabetic ketoacidosis (DKA) if insulin doses are inappropriately reduced in response to modest glycemic improvement, and the drug adds complexity without clear benefit. Some T1D patients with obesity have explored off-label GLP-1 agonist use to support weight loss with variable results and increased complexity; this should only be done with close endocrinology supervision and intensive monitoring. FDA approval for orforglipron (Foundayo) is for chronic weight management in obesity/overweight, with a type 2 diabetes indication still under review; type 1 diabetes use would be off-label and experimental."
          }
        },
        {
          "@type": "Question",
          "name": "Why is orforglipron a big deal beyond just being oral?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The transformational implications extend beyond convenience: (1) Manufacturing scale: small-molecule synthesis uses existing generic drug manufacturing infrastructure, potentially easing the peptide supply crisis that caused 2+ year semaglutide shortages and limited tirzepatide rollout; (2) Global access: no cold-chain requirement means distribution to low- and middle-income countries becomes feasible - currently injectable GLP-1s are essentially unavailable across much of Africa, South America, and Southeast Asia due to refrigeration logistics; (3) Cost reduction: generic competition after patent expiration (mid-2030s) could bring retail cost from $1,000+/month to potentially $20-50/month, analogous to how statins democratized cholesterol management; (4) Patient barrier removal: ~30-40% of candidates for injectable GLP-1s decline due to needle aversion; orforglipron removes this barrier entirely; (5) Development platform: success validates small-molecule agonism of peptide receptors as a drug-discovery strategy, opening the door to oral versions of other peptide drug classes (e.g., GIP agonists, glucagon agonists, incretin combinations). The FDA's approval of orforglipron (Foundayo) in April 2026 marks the beginning of the oral GLP-1 era and likely the peak of the injectable-peptide era - a shift with major public health consequences."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    }
  ]
---

[Skip to content](#main-content)

## Research Use Only

This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy).

I'm 21+ — Enter SiteLeave site

   

[![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/)

[Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools)

Learn

Community

Search ⌘K

[Sign In](/auth?returnTo=%2Fcompound%2Forforglipron)

100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 

1.  [Home](/)
2.  [Compounds](/compare)
3.  Orforglipron 

[Where to buy Orforglipron](/buy/orforglipron) [Orforglipron coupon codes](/coupons/orforglipron) [Orforglipron protocol](/protocol/orforglipron) [Alternatives to Orforglipron](/alternatives-to/orforglipron) [Orforglipron side effects](/side-effects/orforglipron)

1.  [Home](/)

3.  [Compounds](/compare)

5.  Orforglipron 

# Orforglipron

Weight Loss FDA Approved 

Download  PDF

Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons.

Half-Life:  ~29-49 hours (supports once-daily oral dosing) MW:  882.97 g/mol 

Last reviewed: Aug 25, 2026 

[

Weight Loss

Category



](/wiki#cat-weight-loss)

FDA Approved

Research Stage

OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related

## Overview

### Best Price Available

VL

VANDL Labs

$249.99

30 capsules · capsule

[Buy Now](https://www.vandl-labs.com/product/orforglipron/?ref=choncho)

Coupon: `CHON`Copy

Compare 1 vendor

### At A Glance

Mechanism 

Orforglipron (LY3502970; OWL833) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist. It engages the GLP-1 receptor (GLP1R) through a binding mode fundamentally different from native GLP-1 or peptide-based analogs.… 

Half-Life 

~29-49 hours (supports once-daily oral dosing)

Dosing 

Once daily

### Mechanism of Action

Orforglipron (LY3502970; OWL833) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist. It engages the GLP-1 receptor (GLP1R) through a binding mode fundamentally different from native GLP-1 or peptide-based analogs.

**Non-Peptide Binding at a Distinct Receptor Pocket:** Native GLP-1 is a 30-amino-acid peptide whose helix docks into the GLP1R orthosteric site to drive activation - the same general region used by semaglutide, liraglutide, and other peptide analogs. Orforglipron, a small molecule, instead occupies a distinct pocket in the upper helical bundle of the receptor, contacting the extracellular domain (ECD), extracellular loop 2 (ECL2), and transmembrane helices 1, 2, 3, and 7. A high-resolution cryo-EM structure of orforglipron bound to active-state GLP1R showed this creates a unique receptor conformation not adopted with peptide ligands (\[Kawai et al., 2020\]).

**Partial, G-Protein-Biased Agonism (not a full agonist):** Contrary to the assumption that it simply reproduces peptide-agonist pharmacology, orforglipron is a PARTIAL agonist that is BIASED toward Gs/cAMP signaling over beta-arrestin recruitment at GLP1R (\[Kawai et al., 2020\]). Because the Gs/cAMP/PKA arm is the pathway that drives the therapeutically important physiology, this partial, biased profile still delivers robust clinical efficacy, including:

-   Beta-cell insulin secretion (glucose-dependent)
-   Alpha-cell glucagon suppression
-   Hypothalamic POMC/CART neuron activation (appetite suppression)
-   Brainstem vagal satiety signaling
-   Gastric emptying delay

**Pharmacokinetic Profile:** Orforglipron's PK enables once-daily oral dosing:

-   Oral bioavailability: HIGH - mean absolute oral bioavailability ~79% in a human mass-balance study, in sharp contrast to oral semaglutide (Rybelsus, ~1%, which needs the SNAC absorption enhancer) (\[Morse et al., 2025\])
-   Half-life: ~29-49 hours - long enough for once-daily steady-state dosing (\[Pratt et al., 2023\])
-   Tmax: ~6-10 hours after oral administration
-   Not a substrate for the peptidase DPP-4 (it is not a peptide) and not subject to gastric-acid degradation
-   No clinically meaningful food effect: unlike Rybelsus it can be taken with or without food and with no post-dose fasting window, removing the biggest compliance problem of oral semaglutide

**Metabolic Effects (downstream of receptor activation):** Once orforglipron activates GLP1R, the downstream physiology parallels other GLP-1 agonists:

-   Weight loss: primarily via appetite suppression and reduced food intake
-   Glycemic control: meaningful HbA1c reduction in type 2 diabetes via glucose-dependent insulin secretion and glucagon suppression
-   Gastric emptying: delayed, contributing to satiety
-   Cardiometabolic: pooled Phase 2 data showed placebo-adjusted improvements in blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP (\[Wharton et al., 2025\])

**Why "Non-Peptide" Matters:** The small-molecule structure can be made by conventional chemical synthesis (not peptide synthesis or fermentation), is orally and chemically stable, needs no refrigeration, and largely avoids the immunogenicity (anti-drug antibody) risk that can affect peptide drugs.

**Relation to the Injectable GLP-1 Class:** Orforglipron is not structurally related to exendin-4, GLP-1, or semaglutide. It originated from Chugai's OWL833 small-molecule program (developed with Eli Lilly as LY3502970), identified by screening and medicinal-chemistry optimization to yield a novel chemotype that activates the same receptor - analogous to how small-molecule opioid agonists activate the same receptors as endogenous peptide opioids without sharing their peptide structure.

### Overview

Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — [Semaglutide](/compound/semaglutide), [Tirzepatide](/compound/tirzepatide), [Liraglutide](/compound/liraglutide), [Dulaglutide](/compound/dulaglutide), exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access.

Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026.

Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include [Semaglutide](/compound/semaglutide) (injectable GLP-1 peptide), [Tirzepatide](/compound/tirzepatide) (injectable GLP-1/GIP peptide), [Mazdutide](/compound/mazdutide) (injectable GLP-1/glucagon peptide for China), [Retatrutide](/compound/retatrutide) (injectable GLP-1/GIP/glucagon triple agonist peptide), and [Cagrilintide](/compound/cagrilintide) (amylin analog used in combination with GLP-1s).

## Chemical Information

IUPAC Name

Not yet available 

CAS Number

Not yet available 

Molecular Formula

Not yet available 

Molecular Mass

882.97 g/mol (C48H48F2N10O5; PubChem CID 137319706)

## Dosing & Protocols

### Unlock Dosing Protocols

Free account gets you:

-   View beginner, intermediate & advanced protocols 
-   See weight-based dosing calculations 
-   Access cycle length & frequency data 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Research

### Unlock Research Data

Free account gets you:

-   Browse PubMed study summaries 
-   See clinical trial phases & results 
-   Access mechanism of action details 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Interactions

### Contraindications

**Absolute Contraindications:**

-   Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning shared across GLP-1 class
-   Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — boxed warning
-   Prior serious hypersensitivity to orforglipron or its components
-   Pregnancy (insufficient safety data; discontinue at least 2 months before conception)
-   Active lactation (insufficient safety data)

**Relative Contraindications (Use With Caution / Individualized Assessment):**

-   History of pancreatitis (acute or chronic) — weigh benefits vs. risk of recurrence
-   Active gallbladder disease / symptomatic cholelithiasis — rapid weight loss increases gallstone risk
-   Severe gastroparesis or known gastric outlet obstruction
-   Severe chronic kidney disease (eGFR <30 mL/min/1.73m²) — limited safety data
-   Severe hepatic impairment (Child-Pugh C) — limited safety data
-   Active eating disorder (especially anorexia nervosa or restrictive subtypes)
-   Type 1 diabetes mellitus — orforglipron is for T2D and obesity; no established role in T1D and risk of DKA if insulin inappropriately reduced
-   Diabetic retinopathy — rapid glycemic improvement can temporarily worsen retinopathy; ophthalmologic surveillance during initiation

**Drug Interactions Requiring Special Caution:**

-   Insulin, sulfonylureas, meglitinides — significant hypoglycemia risk; reduce doses at initiation
-   Warfarin — potential altered absorption; increased INR monitoring
-   Oral contraceptives — possible altered absorption during first 4 weeks; backup contraception recommended
-   Drugs with narrow therapeutic index and gastric-emptying-dependent absorption (e.g., digoxin) — monitor levels

**Pre-Surgical Considerations:** Patients on GLP-1 agonists (including anticipated for orforglipron) have delayed gastric emptying that may persist longer than standard pre-operative fasting periods. The American Society of Anesthesiologists (2023 guidance) recommends:

-   Hold orforglipron for at least 1-2 weeks before elective surgery requiring anesthesia (if feasible), OR
-   Use extended pre-op fasting (≥8 hours for solids, ≥4 hours for clear liquids), OR
-   Consider rapid sequence induction to minimize aspiration risk
-   Gastric ultrasound assessment of residual contents may be helpful

For urgent/emergent surgery, anesthesiologists should assume full stomach and take aspiration precautions.

**Weight Loss Monitoring:** While orforglipron is designed for weight loss, excessive loss (>1.5-2 lb/week beyond initial water weight) may indicate:

-   Inadequate caloric intake due to severe appetite suppression
-   Possible underlying GI pathology
-   Need for dose reduction

Extreme weight loss with poor nutritional intake can compromise lean mass, bone density, immune function, and menstrual cyclicity (in women of reproductive age).

**Mental Health Considerations:** While FDA and EMA have not identified a causal link between GLP-1 agonists and suicidal ideation/behavior in complete analyses, individual case reports exist. Patients with:

-   Active major depression
-   History of suicidal ideation or self-harm
-   Complex relationship with food / body image issues Should be monitored with mental health support; orforglipron is not absolutely contraindicated but requires thoughtful management.

**Sports and Athletics:** GLP-1 agonists are not currently banned by WADA (World Anti-Doping Agency) or most sporting bodies as of 2026, but athletes should:

-   Verify current prohibited list
-   Ensure adequate caloric intake for training demands
-   Monitor body composition to preserve lean mass and performance
-   Work with sports dietitian to periodize nutrition around training

**Long-Term Safety Unknowns:** As with all newly approved medications, long-term (>10 year) safety data for orforglipron will accumulate post-approval. Current Phase 3 data extends to ~72 weeks of continuous exposure. Areas of ongoing surveillance:

-   Thyroid cancer incidence (MTC-specific)
-   Pancreatic cancer incidence
-   Gallbladder disease rates
-   Bone density changes
-   Mental health outcomes
-   Effects on cognitive function
-   Reproductive/fertility effects

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

Best Price 

$249.99

Best $/mg 

—

Vendors 

1

Listings 

1

capsule

[Sign in for alerts ](/auth)

Form Allcapsule

Sort Price $/mg Vendor

Vendor

Product

Form

Qty

Price

$/mg

Coupon

![VANDL Labs logo](https://www.vandl-labs.com/wp-content/uploads/2026/04/LogoPack_Logo-03-scaled-2.png)

[VANDL Labs](/vendor/vandl-labs)

[50 ](/vendor-trust-scorecard)

🇺🇸 US 

Orforglipron Capsules 30ct

capsule 

30 capsules ● In Stock 

$249.99 BEST 

—

CHON

[Buy](https://www.vandl-labs.com/product/orforglipron/?ref=choncho)

Get Orforglipron Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $249.99

[Sign in to set alerts](/auth)

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Orforglipron.

[Sign in](/auth)

Current low

$249.99

as of Apr 6, 2026

7-day low

—

no 7d data yet

30-day low

—

no 30d data yet

30-day change

— 

baseline building

Tracking since Apr 6, 2026 · 1 data point

### Vendors Selling Orforglipron

[

![VANDL Labs logo](https://www.vandl-labs.com/wp-content/uploads/2026/04/LogoPack_Logo-03-scaled-2.png)

#### VANDL Labs

1 listing · from $249.99 





](/vendor/vandl-labs)

How we score these vendors

Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

[View Scorecard](/vendors/scorecard)

### Related Compounds

[View All](/wiki)

[

### 5-Amino-1MQ

Weight Loss Preclinical 

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).

t½ ~6–12 hours (oral)  50 mg - 150 mg daily (oral or injection) 

Preclinical View Profile 

](/compound/5-amino-1mq)[

### BAM15

Weight Loss Preclinical 

BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (\[Kenwood et al., 2014\]).

Research compound — no established human doses. Animal studies use 10-100 mg/kg 

58 studies View Profile 

](/compound/bam15)[

### Exenatide

Weight Loss FDA-approved 

Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite.

t½ Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks.  5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) 

Preclinical View Profile 

](/compound/exenatide)[

### L-Carnitine

Weight Loss Preclinical 

L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health.

500 mg - 2000 mg daily (oral or injection) 

23241 studies View Profile 

](/compound/l-carnitine)[

### Lipo-C

Weight Loss No clinical trials of the blend (marketed compounded injection) 

Lipo-C (also sold as a MIC or "lipotropic" injection) is a compounded blend of methionine, inositol, and choline, usually with vitamin B12 and sometimes L-carnitine, marketed by medspas and weight-loss clinics to support fat metabolism and energy.

t½ Not applicable to the blend; the water-soluble components (choline, inositol, B-vitamins, carnitine) are cleared over hours to a few days, and excess is largely excreted.  1 mL of a compounded MIC blend intramuscularly, 1 to 2x per week. No standardized dose exists; concentrations vary by compounding pharmacy. 

Preclinical View Profile 

](/compound/lipo-c)[

### Mazdutide

Weight Loss Approved (China, NMPA 2025); investigational in US/EU 

Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.

Research doses — clinical trial protocols vary 

39 studies View Profile 

](/compound/mazdutide)

### Side-by-Side Comparisons

[All Comparisons](/compare)

[Orforglipron vs Semaglutide](/compare/orforglipron-vs-semaglutide "Orforglipron vs Semaglutide")

[

View Full Dosage Guide →

Protocols, calculator & safety for Orforglipron



](/guides/dosage/orforglipron)

### Related Articles

[All Posts](/blog)

[

#### Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For

how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.

5/20/2026 ](/blog/aqasome-nanotechnology-oral-peptides)

### Best Price

VL

VANDL Labs

$249.99

[Buy Now](https://www.vandl-labs.com/product/orforglipron/?ref=choncho)

1 vendors · 1 listings

### Research Score

15 

0 PubMed studies

### Quality Indicators

Data Completeness

63% 

Description 

Mechanism of Action 

Chemical Data 

Dosing Protocols 

Safety Profile 

PubMed Studies 

Interactions 

Vendor Listings 

### Quick Facts

Half-Life

~29-49 hours (supports once-daily oral dosing)

Molecular Weight

882.97 g/mol (C48H48F2N10O5; PubChem CID 137319706)

Trial Phase

FDA Approved

[Full Dosage Guide](/guides/dosage/orforglipron)[Calculate Your Dose](/tools/reconstitution)

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

## Frequently Asked Questions

What makes orforglipron different from oral semaglutide (Rybelsus)?

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist with high oral bioavailability (~79% absolute in human mass-balance studies), so it can be taken any time of day with or without food. Rybelsus is oral semaglutide - still a peptide - that relies on the absorption enhancer SNAC, has only ~1% oral bioavailability, and must be taken fasting with a small amount of water and a 30-minute wait before eating or drinking. Those practical differences translate into large efficacy gaps: at its top dose orforglipron produced ~12.4% weight loss at 72 weeks in Phase 3 (ATTAIN-1), versus roughly 3-5% typically seen with Rybelsus ([Morse et al., 2025 ](https://pubmed.ncbi.nlm.nih.gov/40888509/)).

How does orforglipron's weight loss compare to injectable semaglutide or tirzepatide?

In the Phase 3 ATTAIN-1 trial, orforglipron 36 mg once daily produced ~12.4% mean weight loss (about 27.3 lb) at 72 weeks. That is meaningful for an oral drug, but it came in somewhat below injectable semaglutide 2.4 mg weekly (Wegovy, ~15% at 68 weeks in STEP-1) and well below tirzepatide 15 mg weekly (Zepbound, ~20-21% at 72 weeks in SURMOUNT-1, which adds GIP agonism). So orforglipron does not fully match the strongest injectables - its real advantage is being an oral pill with no food or water timing restrictions, which for a patient who refuses injections is a major benefit.

When will orforglipron be available by prescription?

It is already available in the US. The FDA approved orforglipron on April 1, 2026 under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. Eli Lilly has also filed for weight management and/or type 2 diabetes in dozens of other countries, with the type 2 diabetes indication still under regulatory review in the US. Because it is a small molecule made by conventional chemical synthesis, supply is expected to scale far faster than injectable peptide GLP-1s did.

How is orforglipron's mechanism different from other GLP-1 agonists?

Peptide GLP-1 agonists (semaglutide, liraglutide, and the GLP-1 arm of tirzepatide) engage the receptor's orthosteric site the way native GLP-1 does. Orforglipron, a small molecule, instead binds a distinct pocket in the upper helical bundle of GLP1R - contacting the extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7 - producing a unique active-state receptor conformation. Pharmacologically it behaves as a partial agonist that is biased toward Gas/cAMP signaling over beta-arrestin recruitment; because the Gas/cAMP arm drives the insulinotropic and appetite-suppressing effects, it still delivers strong clinical efficacy ([Kawai et al., 2020 ](https://pubmed.ncbi.nlm.nih.gov/33177239/)).

Can orforglipron be combined with other weight loss medications?

Most evidence supports combining orforglipron with mechanism-distinct agents rather than other GLP-1 agonists (which would be redundant). Leading combinations: (1) amylin analog like [Cagrilintide](/compound/cagrilintide) - Novo Nordisk's CagriSema concept shows ~22.7% weight loss with semaglutide + cagrilintide; orforglipron + cagrilintide should produce similar synergy; (2) SGLT2 inhibitors for T2D - complementary mechanisms with additive glycemic and weight benefits; (3) metformin - standard T2D foundation. Avoid combining orforglipron with other GLP-1 agonists, other GLP-1 receptor modulators, or [Tirzepatide](/compound/tirzepatide) / [Retatrutide](/compound/retatrutide) / [Mazdutide](/compound/mazdutide), which would be pharmacologically redundant at the GLP-1 receptor.

What side effects should I expect on orforglipron?

Expect gastrointestinal symptoms similar to all GLP-1 agonists: nausea (30-50% at therapeutic doses), diarrhea or constipation (20-30%), vomiting (10-20%), reduced appetite (expected therapeutic effect but can feel uncomfortable early). These usually peak during dose escalations and improve within 1-2 weeks at each step. Gradual dose titration significantly reduces intolerance versus faster escalation. Less common but serious: pancreatitis (rare, requires evaluation if severe abdominal pain develops), gallbladder disease (weight loss-related), retinopathy worsening (in patients with existing diabetic retinopathy during rapid glycemic improvement). Long-term theoretical concerns include medullary thyroid carcinoma (rodent signal, no clear human signal), warranting the MTC/MEN2 contraindication shared across the GLP-1 class ([Fras et al., 2023 ](https://pubmed.ncbi.nlm.nih.gov/37369232/)).

Will I regain weight if I stop taking orforglipron?

Yes, most patients regain substantial weight within 12 months of discontinuation. This mirrors the pattern seen with semaglutide (STEP-4 extension trial: ~2/3 of weight regained by 1 year off-drug) and tirzepatide (SURMOUNT-4: similar pattern). GLP-1 agonists are best understood as chronic therapy for chronic disease - analogous to how antihypertensives control blood pressure only while taken. Patients considering orforglipron should plan for long-term or lifelong therapy, with structured lifestyle support (resistance training, protein-forward nutrition, sleep optimization) to maximize the weight maintained if discontinuation becomes necessary. Some patients successfully transition to maintenance doses (e.g., 12 mg daily instead of 36 mg) to sustain partial benefit at lower cost and side effects.

How does orforglipron affect body composition versus just total weight?

Like all GLP-1 agonists, orforglipron produces primarily fat-mass loss but also some lean-mass loss - typically 20-40% of total weight lost is lean tissue. This is a well-documented class effect seen with semaglutide (STEP-1 DEXA substudy), tirzepatide (SURMOUNT DEXA data), and expected for orforglipron. Mitigation strategies include: (1) resistance training 2-3x/week minimum - the single most impactful intervention for lean mass preservation; (2) high-protein intake of 1.2-1.6 g/kg body weight daily; (3) adequate overall calories to support muscle protein synthesis; (4) consideration of adjunctive growth-hormone-axis support such as [Tesamorelin](/compound/tesamorelin), [Ipamorelin](/compound/ipamorelin), or [CJC-1295](/compound/cjc-1295) for patients prioritizing lean mass preservation. DEXA scans every 6-12 months allow objective tracking of body composition changes rather than relying on scale weight alone.

Is orforglipron safe for people with type 1 diabetes?

Orforglipron is not indicated for type 1 diabetes. Its primary mechanisms - glucose-dependent insulin secretion and glucagon suppression - require functional pancreatic beta cells, which T1D patients lack. Using orforglipron in T1D risks diabetic ketoacidosis (DKA) if insulin doses are inappropriately reduced in response to modest glycemic improvement, and the drug adds complexity without clear benefit. Some T1D patients with obesity have explored off-label GLP-1 agonist use to support weight loss with variable results and increased complexity; this should only be done with close endocrinology supervision and intensive monitoring. FDA approval for orforglipron (Foundayo) is for chronic weight management in obesity/overweight, with a type 2 diabetes indication still under review; type 1 diabetes use would be off-label and experimental.

Why is orforglipron a big deal beyond just being oral?

The transformational implications extend beyond convenience: (1) **Manufacturing scale**: small-molecule synthesis uses existing generic drug manufacturing infrastructure, potentially easing the peptide supply crisis that caused 2+ year semaglutide shortages and limited tirzepatide rollout; (2) **Global access**: no cold-chain requirement means distribution to low- and middle-income countries becomes feasible - currently injectable GLP-1s are essentially unavailable across much of Africa, South America, and Southeast Asia due to refrigeration logistics; (3) **Cost reduction**: generic competition after patent expiration (mid-2030s) could bring retail cost from $1,000+/month to potentially $20-50/month, analogous to how statins democratized cholesterol management; (4) **Patient barrier removal**: ~30-40% of candidates for injectable GLP-1s decline due to needle aversion; orforglipron removes this barrier entirely; (5) **Development platform**: success validates small-molecule agonism of peptide receptors as a drug-discovery strategy, opening the door to oral versions of other peptide drug classes (e.g., GIP agonists, glucagon agonists, incretin combinations). The FDA's approval of orforglipron (Foundayo) in April 2026 marks the beginning of the oral GLP-1 era and likely the peak of the injectable-peptide era - a shift with major public health consequences.

## Research Tools

[

### Peptide Calculator

Reconstitution & syringe units



](/tools/reconstitution)[

### Reconstitution Guide

How to mix, step by step



](/guides/how-to-reconstitute-peptides)[

### Nasal Spray Calc

mL per actuation



](/tools/intranasal)[

### Half-Life Visualizer

Decay curves



](/tools/halflife)

## Related Compounds

[View All](/wiki)

[

### 5-Amino-1MQ

Weight Loss Preclinical 

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).

t½ ~6–12 hours (oral)  50 mg - 150 mg daily (oral or injection) 

Preclinical View Profile 

](/compound/5-amino-1mq)[

### BAM15

Weight Loss Preclinical 

BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (\[Kenwood et al., 2014\]).

Research compound — no established human doses. Animal studies use 10-100 mg/kg 

58 studies View Profile 

](/compound/bam15)[

### Exenatide

Weight Loss FDA-approved 

Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite.

t½ Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks.  5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) 

Preclinical View Profile 

](/compound/exenatide)[

### L-Carnitine

Weight Loss Preclinical 

L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health.

500 mg - 2000 mg daily (oral or injection) 

23241 studies View Profile 

](/compound/l-carnitine)[

### Lipo-C

Weight Loss No clinical trials of the blend (marketed compounded injection) 

Lipo-C (also sold as a MIC or "lipotropic" injection) is a compounded blend of methionine, inositol, and choline, usually with vitamin B12 and sometimes L-carnitine, marketed by medspas and weight-loss clinics to support fat metabolism and energy.

t½ Not applicable to the blend; the water-soluble components (choline, inositol, B-vitamins, carnitine) are cleared over hours to a few days, and excess is largely excreted.  1 mL of a compounded MIC blend intramuscularly, 1 to 2x per week. No standardized dose exists; concentrations vary by compounding pharmacy. 

Preclinical View Profile 

](/compound/lipo-c)[

### Mazdutide

Weight Loss Approved (China, NMPA 2025); investigational in US/EU 

Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.

Research doses — clinical trial protocols vary 

39 studies View Profile 

](/compound/mazdutide)

## Side-by-Side Comparisons

[All Comparisons](/compare)

Compare Orforglipron head-to-head: mechanism, half-life, dosing, safety, and live pricing.

[Orforglipron vs Semaglutide](/compare/orforglipron-vs-semaglutide "Orforglipron vs Semaglutide")

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

[Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-orforglipron)

### Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH  for first-order discount.

[Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb)

![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)

### BodyHackGuide

Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews.

[support@bodyhackguide.co](mailto:support@bodyhackguide.co)

[](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide)

Explore

#### Explore

-   [Compare prices](/compare)
-   [Research suppliers](/vendors)
-   [Deals](/deals)
-   [Coupons](/coupons)
-   [Nootropics](/nootropics)
-   [Brain health](/brain-health)
-   [Blog](/blog)
-   [Guides](/guides)

Tools

#### Tools

-   [Reconstitution](/tools/reconstitution)
-   [Dosage calculator](/tools/dosage)
-   [Half-life visualizer](/tools/halflife)
-   [COA lookup](/tools/coa)
-   [Cost calculator](/tools/cost-calculator)
-   [Stack builder](/stack-builder)
-   [All tools →](/tools)

Trust & vendors

#### Trust & vendors

-   [Vendor directory](/vendors)
-   [Trust scorecard](/vendors/scorecard)
-   [Get BHG verified](/vendors/get-vetted)
-   [Scoring methodology](/vendors/methodology)
-   [Peptide cheatsheet](/guides/peptide-cheat-sheet-download)

Company

#### Company

-   [About](/about)
-   [Affiliate disclosure](/affiliate-disclosure)
-   [Editorial standards](/editorial-standards)
-   [Creators](/creators)
-   [Coaches](/coaches)
-   [Privacy](/privacy)
-   [Terms](/terms)
-   [Full site directory →](/site-directory)

**Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy)

hi 👋